NO20062791L - 1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdom - Google Patents
1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdomInfo
- Publication number
- NO20062791L NO20062791L NO20062791A NO20062791A NO20062791L NO 20062791 L NO20062791 L NO 20062791L NO 20062791 A NO20062791 A NO 20062791A NO 20062791 A NO20062791 A NO 20062791A NO 20062791 L NO20062791 L NO 20062791L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- benzo
- dihydro
- derivatives
- alkyl
- Prior art date
Links
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title abstract 3
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- SYZIUAAQNFJPJY-UHFFFAOYSA-N 1,4-dihydro-3,1-benzoxazin-2-one Chemical class C1=CC=C2COC(=O)NC2=C1 SYZIUAAQNFJPJY-UHFFFAOYSA-N 0.000 title 1
- XCXVPQAXJPZYNW-UHFFFAOYSA-N 1h-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound C1=CC=C2C=NS(=O)(=O)NC2=C1 XCXVPQAXJPZYNW-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53708004P | 2004-01-16 | 2004-01-16 | |
| PCT/EP2005/000095 WO2005067933A1 (en) | 2004-01-16 | 2005-01-07 | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062791L true NO20062791L (no) | 2006-08-01 |
Family
ID=34794441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062791A NO20062791L (no) | 2004-01-16 | 2006-06-15 | 1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdom |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7196087B2 (https=) |
| EP (1) | EP1708713B1 (https=) |
| JP (1) | JP4533391B2 (https=) |
| KR (1) | KR100843053B1 (https=) |
| CN (1) | CN1909909B (https=) |
| AR (1) | AR047958A1 (https=) |
| AT (1) | ATE388712T1 (https=) |
| AU (1) | AU2005205016B2 (https=) |
| BR (1) | BRPI0506909A (https=) |
| CA (1) | CA2552681A1 (https=) |
| CO (1) | CO5700763A2 (https=) |
| DE (1) | DE602005005298T2 (https=) |
| ES (1) | ES2302174T3 (https=) |
| IL (1) | IL176631A0 (https=) |
| NO (1) | NO20062791L (https=) |
| RU (1) | RU2006129464A (https=) |
| TW (1) | TW200530222A (https=) |
| WO (1) | WO2005067933A1 (https=) |
| ZA (1) | ZA200605434B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114244A (zh) * | 2004-09-30 | 2011-07-06 | 弗·哈夫曼-拉罗切有限公司 | 治疗认知障碍的组合物和方法 |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| AU2005316739A1 (en) * | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Spiro derivatives as lipoxygenase inhibitors |
| BRPI0613430A2 (pt) * | 2005-07-13 | 2011-01-11 | Hoffmann La Roche | compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| CN101600698B (zh) * | 2006-09-11 | 2012-01-11 | 欧加农股份有限公司;药典有限责任公司 | 喹唑啉酮和异喹啉酮乙酰胺衍生物 |
| WO2008073958A2 (en) | 2006-12-12 | 2008-06-19 | Wyeth | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| MX2010014394A (es) * | 2008-06-20 | 2011-05-19 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina. |
| EP2328881A1 (en) * | 2008-09-08 | 2011-06-08 | F. Hoffmann-La Roche AG | 5-substituted benzoxazines |
| US20110288086A1 (en) | 2010-05-21 | 2011-11-24 | Jianqi Li | Polycyclic quinazolines, preparation thereof, and use thereof |
| IL309982A (en) * | 2016-11-15 | 2024-03-01 | Univ Temple | New modulators of 5-hydroxytryptamine receptor 7 and a method of using them |
| MX2021013135A (es) | 2019-04-29 | 2021-11-25 | Solent Therapeutics Llc | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. |
| JP7696354B2 (ja) * | 2019-10-21 | 2025-06-20 | アライリオン インコーポレイテッド | 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642791A (en) | 1969-08-13 | 1972-02-15 | Sandoz Ag | Morpholino-1-substituted-2(1h)-quinazolinones |
| JPS5271483A (en) | 1975-12-11 | 1977-06-14 | Sumitomo Chem Co Ltd | Synthesis of 2(1h)-quinazolinone derivatives |
| CN1015459B (zh) * | 1985-06-06 | 1992-02-12 | 田边制药株式会社 | 喹唑啉酮化合物的制备方法 |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| AU6423298A (en) | 1997-03-26 | 1998-10-20 | Sumitomo Pharmaceuticals Company, Limited | 4-arylmethylene-1,4-dihydro-2h-azine derivatives |
| DK1028950T3 (da) | 1997-10-28 | 2003-09-01 | Warner Lambert Co | 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler |
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| JP2003513075A (ja) * | 1999-11-05 | 2003-04-08 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 複合５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体活性を有するイソキノリンおよびキナゾリン誘導体 |
| AU1626001A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| JP2004521892A (ja) * | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| ES2268113T3 (es) * | 2001-06-15 | 2007-03-16 | F. Hoffmann-La Roche Ag | Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6. |
| GB0203804D0 (en) * | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| PT1506179E (pt) * | 2002-05-13 | 2006-06-30 | Hoffmann La Roche | Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes |
-
2005
- 2005-01-07 JP JP2006548231A patent/JP4533391B2/ja not_active Expired - Fee Related
- 2005-01-07 RU RU2006129464/04A patent/RU2006129464A/ru unknown
- 2005-01-07 KR KR1020067014320A patent/KR100843053B1/ko not_active Expired - Fee Related
- 2005-01-07 DE DE602005005298T patent/DE602005005298T2/de not_active Expired - Lifetime
- 2005-01-07 BR BRPI0506909-2A patent/BRPI0506909A/pt not_active IP Right Cessation
- 2005-01-07 EP EP05700747A patent/EP1708713B1/en not_active Expired - Lifetime
- 2005-01-07 ES ES05700747T patent/ES2302174T3/es not_active Expired - Lifetime
- 2005-01-07 CN CN2005800026123A patent/CN1909909B/zh not_active Expired - Fee Related
- 2005-01-07 WO PCT/EP2005/000095 patent/WO2005067933A1/en not_active Ceased
- 2005-01-07 CA CA002552681A patent/CA2552681A1/en not_active Abandoned
- 2005-01-07 AT AT05700747T patent/ATE388712T1/de active
- 2005-01-07 AU AU2005205016A patent/AU2005205016B2/en not_active Ceased
- 2005-01-13 AR ARP050100106A patent/AR047958A1/es not_active Application Discontinuation
- 2005-01-13 TW TW094101029A patent/TW200530222A/zh unknown
- 2005-01-14 US US11/035,506 patent/US7196087B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 NO NO20062791A patent/NO20062791L/no not_active Application Discontinuation
- 2006-06-29 IL IL176631A patent/IL176631A0/en unknown
- 2006-06-30 ZA ZA200605434A patent/ZA200605434B/en unknown
- 2006-07-13 CO CO06068258A patent/CO5700763A2/es not_active Application Discontinuation
-
2007
- 2007-02-07 US US11/703,424 patent/US7365063B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005067933A1 (en) | 2005-07-28 |
| TW200530222A (en) | 2005-09-16 |
| US7365063B2 (en) | 2008-04-29 |
| JP2007517826A (ja) | 2007-07-05 |
| KR100843053B1 (ko) | 2008-07-01 |
| CA2552681A1 (en) | 2005-07-28 |
| EP1708713A1 (en) | 2006-10-11 |
| ATE388712T1 (de) | 2008-03-15 |
| JP4533391B2 (ja) | 2010-09-01 |
| DE602005005298T2 (de) | 2009-03-12 |
| AR047958A1 (es) | 2006-03-15 |
| US20050165001A1 (en) | 2005-07-28 |
| AU2005205016A1 (en) | 2005-07-28 |
| CO5700763A2 (es) | 2006-11-30 |
| ES2302174T3 (es) | 2008-07-01 |
| RU2006129464A (ru) | 2008-02-27 |
| KR20060126720A (ko) | 2006-12-08 |
| CN1909909A (zh) | 2007-02-07 |
| ZA200605434B (en) | 2008-02-27 |
| IL176631A0 (en) | 2006-10-31 |
| EP1708713B1 (en) | 2008-03-12 |
| US20070149510A1 (en) | 2007-06-28 |
| AU2005205016B2 (en) | 2010-07-15 |
| CN1909909B (zh) | 2010-12-15 |
| BRPI0506909A (pt) | 2007-05-29 |
| US7196087B2 (en) | 2007-03-27 |
| DE602005005298D1 (de) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062791L (no) | 1-benzyl-5-piperazin-1-yl-34 4 dihydro-lH-kinazolin-2-on derivater og de respektive 1H-benzo(1,2,6) tiadiazin-2,2-dioksid og 1, 4-dihydro-benzo (D) (1,3)oksazin-2-on derivater som modulatorer av 5-hydroksytryptamin reseptor (5-HT) for behandling av sykdom | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| DE602004024880D1 (de) | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten | |
| UA74066C2 (en) | Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment | |
| MX2009001036A (es) | Pirazolopirimidinas, proceso para su preparacion y su uso como medicina. | |
| CY1116119T1 (el) | Παραγωγα ισοξαζολο-πυριδινης | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| AR036057A1 (es) | Compuestos derivados 4-piperazinil indol, su uso, un proceso para prepararlos y composiciones farmaceuticas que los comprenden | |
| EA201001178A1 (ru) | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| MA31180B1 (fr) | Procede de synthese de composes 2-aminothiazole comme inhibiteurs de kinase | |
| EA201000314A1 (ru) | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны | |
| RU2005136355A (ru) | Производные сульфонамида, их получение и применение в качестве лекарственных средств | |
| JP2005513016A5 (https=) | ||
| MX2009011051A (es) | Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble. | |
| MX2009009121A (es) | Aminoamidas como antagonistas de orexina. | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| MX2012006789A (es) | Derivados de etinilo. | |
| RU2005117965A (ru) | Замещенные бензоксазиноны и их применение | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| MXPA05010646A (es) | Pirazoles sustituidos. | |
| PE20040763A1 (es) | Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6 | |
| FR2801585B1 (fr) | Nouveaux antagonistes des recepteurs de l'ii-8 | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| DE602006011725D1 (de) | 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors | |
| MX2009010243A (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |